CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 10 enrolled
Drug / intervention
monoclonal antibody hu3S193biological
Likely dose
Not stated in record
Key inclusion· 5
  • ✓Pathologically confirmed small cell lung cancer
  • ✓Measurable disease with at least one lesion ≥2 cm not previously irradiated
  • ✓Disease progression after 1, 2, or 3 prior chemotherapy regimens
  • ✓Tumor tissue positive for Lewis Y expression
Key exclusion· 6
  • ✕Clinically significant cardiac disease (NYHA Class III/IV)
  • ✕Uncontrolled brain or leptomeningeal metastases
  • ✕GI bleed within preceding 6 months
  • ✕Prior exposure to mouse monoclonal antibody

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00084799
NCT00084799Phase 1Completed
CompareCT.gov

A Multiple-Dose Targeting Study of hu3S193 in Patients With Small Cell Lung Cancer

Ludwig Institute for Cancer Research·interventional·Posted Jun 11, 2004·Updated Oct 4, 2023

In Brief

A Phase 1 clinical trial evaluating monoclonal antibody hu3S193 for Lung Cancer. Completed, enrolled 10 participants across 1 site.

Detailed Summary

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: This phase I trial is studying the side effects of monoclonal antibody therapy in treating patients with progressive small cell lung cancer (SCLC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 1CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 11, 2004
Enrollment StartJul 26, 2004
Primary CompletionJan 25, 2006
Study CompletionDec 20, 2006
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 22.1 years ago

Interventions

monoclonal antibody hu3S193biological